Фармакологічні властивості нової комбінованої мазі з етонієм

Abstract

The pharmacological study of the new combined ointment with aethonium for the treatment of the wound process was carried out. Based on the results of the experimental studies, a wide range of the pharmacological actions of the ointment was established. An ointment with aethonium in vitro has shown an antimicrobial effect against the standard strains of S. aureus, E. coli, P. aeruginosa, B. subtilis and C. albicans. According to antimicrobial activity as to standart strains of microorganisms, ointment was not inferior to the reference medicine - Levomecol ointment. At the same time as to fungistatic effect against C. albicans, the ointment with aethonium was more effective, than other reference drugs, excepting Inflarax. The antimicrobial activity of the new ointment relative to the hospital-acquired strains of S. aureus, E. coli, P. aeruginosa, P. vulgaris was comparable to that of the Inflarax and Oflocaine comparison drugs, and relative to K. pneumoniae, significantly exceeded their efficacy. The antimicrobial properties of the original ointment with aethonium are combined with a pronounced analgesic, anti-inflammatory and wound-healing effect. In particular, on the model of terpentine dermatitis ointment with aethonium showed pronounced antiinflammatory activity (77,8 %), which exceeded that of Inflarax (72,2 %), Levomecol (62,7 %) and Oflocaine (47,3 %). At a model of somatic pain in rats (thermal tail irritation), the ointment with aethonium showed a high analgesic activity and exceeded all the com¬parative drugs in effectiveness. On the model of linear cut wound the ointment with aethonium had a pro¬nounced reparative effect, superior to the effects of the Inflarax ointment and Oflocaine. According to the results of experimental studies, a new ointment with aethonium is recommended for further in-depth preclinical and clinical research with the goal of creating an original domestic drug for treating the wound process.